Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer

Cancer MedicineCai L, et al. | May 29, 2020

Advertisement

Researchers evaluated the oncolytic activities of new recombinant coxsackievirus B3 (CVB3) with genetically inserted basic peptides in lung cancer. Recombinant CVB3 was generated in Vero cells, with or without genetically inserted basic peptides. Experts assessed the antitumor activities by undertaking in vitro and in vivo experiments using nude mouse models bearing human lung carcinoma xenografts. Significantly higher pH values within tumors was noted in relation to recombinant CVB3 with genetically inserted basic peptides. Significantly less tumor advancement was demonstrated by mice managed with recombinant CVB3, and recombinant CVB3 with genetically inserted basic peptides seemed to cause enhancement of tumor suppression. Overall, findings revealed strong antitumor activities of recombinant CVB3, particularly those with fused basic peptides, along with no excessive immune responses evoked.

Read the full article on Cancer Medicine

Advertisement